Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy, Focal Seizures, Partial Seizures

Interventions

DRUG: Natalizumab
OTHER: Placebo

Sponsor

Biogen